PROFESSIONAL EDITION

The largest community of pharma leaders

Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

WATERTOWN, Mass.–(BUSINESS WIRE)–Forma Therapeutics announces the first patient dosed in Phase 1 clinical trial evaluating FT-7051 in metastatic castration-resistant prostate cancer.

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles